New treatment for schizophrenia discovered

July 1, 2013, University of Helsinki
Change in symptoms (PANSS score) during the study. Credit: J. Ekelund / University of Helsinki

A research group led by professor Jesper Ekelund showed that by giving a very large dose of famotidine (200 mg daily), sufficient amounts of the drug are able to penetrate the so-called blood-brain barrier to affect the histamine system in the brain.

Famotidine has been used for the treatment of since the 1980s, but at regular dosing, famotidine almost does not enter the brain at all, since the brain is protected by the blood-brain barrier. By increasing the dosage five-fold the drug is able to enter the brain and affect the histamine system.

"Already after one week the symptoms of persons suffering from started to decrease and after four weeks of treatment the symptoms had decreased statistically significantly. The patients that participated in the study were also positively disposed towards the treatment," says Ekelund.

Thirty persons suffering from schizophrenia participated in the study. The patients had been on sickness pension for at least five years and were randomly divided into two groups, one which received famotidine and one which received placebo. All of the patients who took famotidine responded positively to the treatment while the symptoms of those who were on a placebo did not change.

Schizophrenia is the most common and severe , and is the cause of at least half of all treatment days. No randomized, controlled trials in humans that test the effect of H2 in schizophrenia have been published so far.

Innovation in psychiatric medication urgently needed

Since 1963, when the subsequent Nobel prize winner Arvid Carlsson showed that dopamine has a central role in psychosis, the so called - has been central in psychosis. All presently available medications for psychosis are based around this principle. Since is all too often incomplete and side effects common, there is still a great, unmet medical need for medications with other mechanisms of action. Many other signaling substances have been the focus of attention, but so far, the brain histamine system has most widely been regarded as important only with regard to side effects of many psychosis medications.

"Famotidine shouldn't be used directly as treatment for schizophrenia until long-term use of a dose of this size has been proved safe. However, our study shows that the histamine system in the brain offers a novel approach to treating psychosis. This should lead to increased efforts by the pharmaceutical industry to develop medications based on this histamine-based mechanism," says Ekelund.

Famotidine works by blocking the histamine H2 receptor. There are important neurons in the brain that use histamine as their primary signaling substance. These neurons have an important role as regulators of other signaling substances. From animal research, it is known that by affecting the histamine system, one can also affect other signaling substances that are known to be involved in schizophrenia.

The project has already received international recognition. Katarina Meskanen, one of the members of Ekelunds research group, was awarded the Young Scientist Award of the SCNP (Scandinavian College of Neuropsychopharmacology) and the project has been awarded substantial funding (306,000 USD) from the Stanley foundation for follow-up studies.

The research group will replicate the finding through a larger, multinational study in collaboration with Karolinska Institutet in Sweden, where the study is coordinated by professor Jari Tiihonen.

Explore further: Narcolepsy study finds surprising increase in neurons that produce histamine

More information: Meskanen, K. et al. A Randomized Clinical Trial of Histamine 2 Receptor Antagonism in Treatment-Resistant Schizophrenia, Journal of Clinical Psychopharmacology , Volume 33, Number 4, August 2013 (online June 2013).

Related Stories

Narcolepsy study finds surprising increase in neurons that produce histamine

June 3, 2013
A new study provides surprising evidence that people with narcolepsy have an increased number of neurons that produce histamine, suggesting that histamine signaling may be a novel therapeutic target for this potentially disabling ...

Zebrafish reveals central regulator for development of brain histamine system

February 5, 2013
Research has shown that mutations in the psen1 gene are common in the familial forms of Alzheimer's disease, and the Presenilin-1 protein that the gene encodes is known to be involved in the cleavage of the amyloid precursor ...

Long-term ADHD treatment increases brain dopamine transporter levels, may affect drug efficacy

May 15, 2013
Long-term treatment of attention deficit/hyperactivity disorder (ADHD) with certain stimulant medications may alter the density of the dopamine transporter, according to research published May 15 in the open access journal ...

High levels of glutamate in brain may kick-start schizophrenia

April 18, 2013
An excess of the brain neurotransmitter glutamate may cause a transition to psychosis in people who are at risk for schizophrenia, reports a study from investigators at Columbia University Medical Center (CUMC) published ...

Psychiatric medication effects on brain structure

May 8, 2012
It is increasingly recognized that chronic psychotropic drug treatment may lead to structural remodeling of the brain. Indeed, clinical studies in humans present an intriguing picture: antipsychotics, used for the treatment ...

Scientists unpack testosterone's role in schizophrenia

April 26, 2013
Testosterone may trigger a brain chemical process linked to schizophrenia but the same sex hormone can also improve cognitive thinking skills in men with the disorder, two new studies show.

Recommended for you

Study listens in on speech development in early childhood

January 15, 2018
If you've ever listened in on two toddlers at play, you might have wondered how much of their babbling might get lost in translation. A new study from the University of Toronto provides surprising insights into how much children ...

Study suggests people dislike you more for humblebragging than for regular boasting

January 12, 2018
A team of researchers from Harvard University and UNC-Chapel Hill has conducted a study regarding humblebragging—in which a person boasts about an achievement but tries to make it sound less boastful by minimizing it—and ...

Can writing your 'to-do's' help you to doze? Study suggests jotting down tasks can speed the trip to dreamland

January 11, 2018
Writing a "to-do" list at bedtime may aid in falling asleep, according to a Baylor University study. Research compared sleep patterns of participants who took five minutes to write down upcoming duties versus participants ...

Study identifies brain circuit controlling social behavior

January 11, 2018
A new study by researchers at Roche in Basel, Switzerland has identified a key brain region of the neural circuit that controls social behavior. Increasing the activity of this region, called the habenula, led to social problems ...

Tamper-resistant oxycodone tablets have no impact on overall opioid use

January 11, 2018
The introduction of tamper-resistant opioid tablets does not have an effect on rates of opioid use or harms at a population level, according to a new study led by the National Drug and Alcohol Research Centre (NDARC) at UNSW ...

Suicides by drugs in U.S. are undercounted, new study suggests

January 11, 2018
The rate of suicides by drug intoxication in the United States may be vastly underreported and misclassified, according to a new study co-written by Mark Kaplan, professor of social welfare at the UCLA Luskin School of Public ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.